GLP-RT
COA published
A synthetic triple receptor agonist peptide studied in in-vitro GIP, GLP-1 and glucagon receptor binding research.
From$79.00Select size
GLP-TRZ
CAS2023788-19-2MEASURED PURITY99.71%
A dual GIP/GLP-1 receptor agonist peptide studied in comparative receptor-affinity research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- In stock
Select size
Quantity
1
Total
$105.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch LU-TR30-0726-A · Certificate of Analysis available
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
Tirzepatide is a synthetic 39-amino-acid peptide based on the native GIP sequence, engineered to act at two receptors rather than one. It carries a C20 fatty diacid moiety for albumin binding and half-life extension, and non-natural amino acid substitutions for protease resistance. The design question it represents — whether adding GIP receptor activity to GLP-1 receptor activity produces something different from either alone — is what the dual-agonist literature is about.
What has been characterised
Characterised as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), with an unbalanced profile favouring GIPR. The receptor-level and structural literature is cited below, including a 2026 Journal of Medicinal Chemistry paper on the discovery of a balanced GLP-1/GIP dual agonist by molecular dynamics evolution, which is useful for understanding what “balance” means in this class. Receptor target and structure only. Not FDA-approved in this form; supplied for laboratory research use only.
Sources
- 1.“Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution.” J Med Chem, 2026. PMID 42125916
- 2.“Glucose-dependent insulinotropic polypeptide (GIP).” Mol Metab, 2025. PMID 40024571
- 3.“Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.” Nature, 2017. PMID 28538729
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
SEMA
An acylated GLP-1 receptor agonist analog studied in receptor-binding and peptide-stability research.
From$54.00Select size
AOD-9604
COA published
A modified C-terminal fragment of human growth hormone (176-191) studied in structural and receptor research.
$49.00Notify me
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.